Grants to USA Healthcare Professional, Academic, and Community Organizations and Institutions for Therapies to Advance the Treatment of Multiple Myeloma

NCCN Request for Proposals (RFP): NCCN Pfizer Investigator-Sponsored Research Project to Evaluate the Effectiveness of Elranatamab in the Treatment of Multiple Myeloma

Agency

Foundation

GrantWatch ID#

208549

Funding Source

NATIONAL COMPREHENSIVE CANCER NETWORK
Pfizer Global Medical Grants

Geographic Focus

All USA

Important Dates

LOI Date: 05/10/23
Deadline: 08/02/23 5:00 PM Eastern

Grant Description

Grants to USA healthcare professional organizations, academic and community health centers, and institutions for therapies to advance the treatment of Multiple Myeloma. Applicants are required to submit an LOI prior to a full grant application. Funding is intended to determine the efficacy of the BCMA bispecific antibody elranatamab to advance the treatment of MM and toxicity management.

The National Comprehensive Cancer Network® (NCCN) and Pfizer Global Medical Grants are collaborating to offer a new grant opportunity seeking proposals for investigator-sponsored research with elranatamab. Pfizer (hereafter, “Grantor”) is providing research grants to support clinical research studies to further evaluate the effectiveness of elranatamab in the treatment of Multiple Myeloma.

Studies evaluating the BCMA bispecific antibody elranatamab to advance the treatment of MM and toxicity management including, but not limited to:

Studies exploring the optimal use of elranatamab;

In combination, or optimal sequencing, with novel agents;
Dose/schedule optimization and fixed duration;
Administration and resource utilization;

Special populations;
Infection and CRS diagnosis, monitoring and management, including mitigation strategies;
Exploration of novel methods or alternative health care models that improve health equity and patient/care-giver experience during treatment with elranatamab, including technology for patient monitoring or toxicity assessment;

Must be included/integrated within a clinical study; and
Must be sustainable and reproducible.

Recipient

Additional Eligibility Criteria

Geographic Scope: United States

Eligibility Criteria: Investigators from the following organizations may apply:
- PIs must be from US Institutions only; ex-US sub-sites are allowed.
- Academic health care centers.
- Community health care centers.
- Health care professional organizations and other organizations related to health care improvement.
- Health technology companies if partnered with a health care delivery organization who must serve as lead applicant.

- Collaboration between Institutions is strongly encouraged to foster interactive sharing of knowledge and expertise, and to utilize the combined clinical strengths of both Institutions.
- Proposal submissions from junior faculty are encouraged.
- Trainees may participate as a sub-investigator under appropriate mentorship from a PI.

Ineligible

Specific areas considered out of scope or excluded include:
- Exclusively preclinical/non-clinical studies (correlative studies included in a clinical study will be accepted);
- Real World Evidence only studies;
- Randomized, Phase 2/3 studies;
- Studies dependent on access to banked samples from the MagnetisMM Clinical Development Program;
- Studies evaluating elranatamab in smoldering MM or AL amyloidosis;
- Studies looking at QOL only (studies including QOL and additional end points in a clinical study will be accepted);
- Studies involving opioids; and
- Studies not involving elranatamab.

Proposals duplicative of completed, ongoing, or planned studies will not be considered.

Grant Recipient will use the Funding solely for purposes of the Project. The Funding may not be used to pay physicians or other health care providers or health care institutions for referring potential subjects (if any) for enrolment in the Project. If a third party is providing funding for the Project, Grant Recipient will use the Funding only for those Project activities that are not covered by such third-party funding. No portion of the Funding may be used to purchase capital equipment such as computers, iPhones, tablets, appliances, machinery, camera equipment, sensors, etc.

Grant Recipient may not use the Funding to: (i) pay travel, lodging, registration fees, or personal expenses for Project participants; or (ii) purchase and distribute items to Faculty or Project participants that possess a discernible value on the open market (e.g., textbooks). The Funding may be used for food and/or beverages for Faculty or Project participants, unless Pfizer Inc. is a party to this Agreement. If Pfizer Inc. is the Pfizer entity that is party to this Agreement and is providing the Funding, no portion of the Funding may be used for food and/or beverages for Project participants, per Pfizer Inc. policy. Note that the rationale for this is that Pfizer Inc. is subject to different policy requirements relating to provision of support for food and beverage than some other Pfizer entities around the globe.

Pre-Application Information

Key Dates:
- RFP release date: March 29, 2023
- LOI submission deadline: May 10, 2023
- LOI notification date: June 21, 2023
- Full Proposal submission deadline: August 2, 2023
- Anticipated grant award notification date: September 13, 2023
(Please note that the submission deadline is 5:00 PM Eastern)

Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety. To view the core terms of agreement, see Supporting Documents, below.

All applicants will be notified via email by the dates noted above.

Applicants may be asked for additional clarification during the review period.

Additional Funding Information

Estimated Total Program Funding:

$5,000,000

Number of Grants

The intent is to fund 3-5 studies.

Estimated Size of Grant

There is a funding cap of $1.25 million per study. Exceptional studies with budgets above this amount will be considered based on scientific merit and must contain a robust justification.

Term of Contract

- Commencement (defined as first patient receiving first dose of study drug): no later than nine (9) months of notice of study approval.
- Complete accrual: within five (5) years of commencement.
- Reporting/Dissemination of results in Manuscript Form: no later than nine (9) months after study endpoint achieved.

Contact Information

Application: http://www.cybergrants.com/pfizer/loi

If you have questions regarding this RFP, please direct them in writing to Nicole Zion, Clinical Research Manager, at zion@nccn.org and Amanda Kaczerski, Director, Grant Officer Oncology, at amanda.kaczerski@pfizer.com with the subject “NCCN Pfizer Elranatamab RFP”.

Pfizer Inc.
235 East 42nd Street
New York, NY 10017

Grants to USA Healthcare Professional, Academic, and Community Organizations and Institutions for Therapies to Advance the Treatment of Multiple Myeloma

NCCN Request for Proposals (RFP): NCCN Pfizer Investigator-Sponsored Research Project to Evaluate the Effectiveness of Elranatamab in the Treatment of Multiple Myeloma

We have foundations for

We have grants for

Cookies